"In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"

#Leukemia #TyrosineKinase #BTKInhibitor

https://www.nejm.org/doi/full/10.1056/NEJMoa2211582?query=featured_home